期刊文献+

肺腺癌MSCT影像特征与EGFR突变相关性分析 被引量:4

Correlation study on multi-slice spiral computed tomography findings and epidermal growth factor receptor mutations in patients with lung adenocarcinoma
原文传递
导出
摘要 目的探讨周围型肺腺癌患者CT影像及临床病理特征与表皮生长因子受体(EGFR)突变的相关性。方法分析2017年9月至2018年4月于我院胸外科行手术治疗、术后病理确诊为周围型肺腺癌,并对术后大体病理标本进行EGFR基因检测的157例患者。由两名高年资影像科医生分别独立对术前一个月内胸部CT阅片分析,评估其影像特征,并结合临床、病理特征探讨EGFR突变的相关因素,利用Fisher精确检验、χ2检验、t检验、绘制ROC曲线进行分析,P<0.05为差异有统计学意义。结果EGFR突变在MSCT影像表现中,有毛刺组突变率为65.1%(P=0.012),有胸膜凹陷组为64.6%(P=0.044),有磨玻璃影组为70.3%(P=0.013),具有统计学差异。女性患者中EGFR突变占68.0%(P=0.002),不吸烟患者中占69.2%(P=0.000),腺泡型、贴壁型、微乳头型、乳头型、实性型、浸润性粘液型,EGFR突变率分别为:68.5%、60.9%、50.0%、43.8%、22.2%、0.0%(P=0.003),差异有统计学意义。多变量回归分析显示:将所有显著特征统一预测EGFR突变时,ROC曲线的AUC为0.718。结论原发性肺腺癌患者,EGFR突变易发生于女性不吸烟患者中,在腺泡型、贴壁型病理亚型易发生。影像学上伴有磨玻璃影,病灶边缘有毛刺、胸膜凹陷征的肿瘤易发生EGFR突变。 Objective To investigate the correlation of clinical,pathological and multi-slice spiral computed tomography(MSCT)findings and epidermal growth factor receptor(EGFR)mutations in the patients with lung adenocarcinoma.Methods A total of 157 patients with lung adenocarcinoma who underwent surgery and were confirmed to suffer from peripheral lung adenocarcinoma pathologically after operation in the Department of Chest Surgery in our hospital from September 2017 to April 2018 were collected for this study.The EGFR status was respectively tested for the postoperative specimens.Two senior radiologists independently analyzed the chest preoperative MSCT within one month and evaluated the relevant factors of EGFR mutations through analyzing the clinical information and the pathological features.All the data were analyzed with Chi-squared test,Fisher′s exact test,and Student′s t test.The ROC curves were statistically analyzed.And P<0.05 was considered statistically significant.Results On the CT images,the mutation rates of EGFR in the tumors with spiculation,pleural indentation and ground-glass opacity(GGO)were 65.1%(P=0.012),64.6%(P=0.044)and 70.3%(P=0.013),respectively,and statistical significant difference was found.The mutation rates of EGFR in the tumors accounted for 68.0%in the female patients(P=0.002)and 69.2%in the non-smoking patients(P=0.000).The pathological subtypes of lung adenocarcinoma in this cohort included:acinar,lepidic,micro-papillary,papillary,solid and infiltrating mucinous subtypes,whose mutation rates of EGFR were 68.5%,60.9%,50.0%,43.8%,22.2%,and 0.0%,respectively,and statistical significant difference was found(P=0.003).Multivariate logical analysis showed that when all the significant characteristics of EGFR mutations were correlated,the AUC of the ROC curve was 0.718.Conclusion Among the patients with primary lung adenocarcinoma,EGFR mutations tend to occur in women and non-smokers.Mutations of EGFR are mostly in genes 19 and 21,which are prone to occur in the acinar type and lepidic type of lung adenocarcinoma.Mutations of EGFR often occur in the early stage of lung adenocarcinoma.In the terms of MSCT appearance,EGFR mutations more likely occur in the tumors with GGO,spiculation and pleural indentation.
作者 卢晓倩 孟繁杨 窦乐 曹殿波 Lu Xiaoqian;Meng Fanyang;Dou Le;Cao Dianbo(Radiology Department, First Affiliated Hospital, Jilin University, Changchun 130021, China)
出处 《中华肺部疾病杂志(电子版)》 CAS 2020年第3期319-323,共5页 Chinese Journal of Lung Diseases(Electronic Edition)
基金 国家卫生健康委员会资助项目(131025000000170001) 吉林省科技厅资助项目(20170622009JC) 吉林大学省校共建项目(SXGJXX2017-8)。
关键词 放射组学表皮生长因子 肺肿瘤 多层螺旋计算机断层扫描 Epidermal growth factor receptor Lung tumor Multi-slice spiral computed tomography
  • 相关文献

参考文献2

二级参考文献46

  • 1Pan 0. Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas[J].J Mol Diagn, 2005, 7(3):396-403.
  • 2Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Science[J]. N Engl J Med, 2004, 350(21):2129-2139.
  • 3Paez JG, Jnne PA, LeeJC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676): 1497-1500.
  • 4Shepherd FA, Rodrigues Pereira j, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med, 2005, 353(2):123-132.
  • 5Douillard JY, Laporte S, Fossella F, et al. Comparison of docetax- el- and vinca alkaloid-based chemotherapy in the first-line treat-ment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials[J]. J Thorac Oncol, 2007, 2(10): 939-946.
  • 6Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutation are common in lung cancers from"never smokers"and are associat- ed with sensitivity of tumors to gefitinib and erlotinib[]]. Proc Nat Acad Sci U S A, 2004, 101(36):13306-13311.
  • 7Zhao LD, Li JL, Wang Y, et al. Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-smaU cell lung cancer[J]. Zhonghua Zhong Liu Za Zhi, 2011, 33(3):217-221.
  • 8Won YW, HanJY, Lee GK, et al. Comparison of clinical outcome of patients with non-small--ceU lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations[]]. J Clin Pathol, 2011, 64(11):947-952.
  • 9Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WfFOG3405): an open label, randomised phase 3 triM[J]. Lancet Oncol, 2010, 11(2): 121-128.
  • 10Rosell R, Moran T, Carcereny E, et al. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain[]]. Clin Transl Oncol, 2010, 12(2):75-80.

共引文献86

同被引文献37

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部